Literature DB >> 11097601

Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3.

.   

Abstract

OBJECTIVE: To investigate possible risk factors for age-related macular degeneration (AMD) in participants in the Age-Related Eye Disease Study (AREDS).
DESIGN: Case-control study. PARTICIPANTS: Of the 4757 persons enrolled in AREDS, 4519 persons aged 60 to 80 years were included in this study. The lesions associated with AMD ranged from absent in both eyes to advanced in one eye. MAIN OUTCOME MEASURES: Stereoscopic color fundus photographs of the macula were used to place participants into one of five groups, based on the frequency and severity of lesions associated with AMD. Participants with fewer than 15 small drusen served as the control group.
RESULTS: Staged model building techniques were used to compare each of the four case groups with the control group. Increased age was a consistent finding of all four of the case groups compared with the control group, and all the following associations were age adjusted. Persons with either intermediate drusen, extensive small drusen, or the pigment abnormalities associated with AMD (group 2) were more likely to be female, more likely to have a history of arthritis, and less likely to have a history of angina. Persons with one or more large drusen or extensive intermediate drusen (group 3) were more likely to use hydrochlorothiazide diuretics and more likely to have arthritis. Hypertension, hyperopia, presence of lens opacities, and white race were also found more frequently in this group as well as in persons with neovascular AMD (group 5). Only persons in group 5 were more likely to have an increased body mass index, whereas persons with geographic atrophy (group 4) as well as those in groups 3 and 5 were more likely to have completed fewer years in school or to be smokers. Those with geographic atrophy were also more likely to use thyroid hormones and antacids.
CONCLUSIONS: Our findings for smoking and hypertension, which have been noted in previous studies, suggest that two important public health recommendations, the avoidance of smoking and the prevention of hypertension, may reduce the risk of developing AMD. Other associations, such as those for hyperopia, lens opacities, less education, female gender, increased body mass index, and white race, which have been noted in other studies, are also seen in the AREDS population. The increased use of thyroid hormones and antacids in persons with geographic atrophy and the increased likelihood of arthritis or hydrochlorothiazide use in persons with one or more large drusen or extensive intermediate drusen have not been previously reported and need additional investigation.

Entities:  

Mesh:

Year:  2000        PMID: 11097601      PMCID: PMC1470467          DOI: 10.1016/s0161-6420(00)00409-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  47 in total

1.  Risk factors in age-related maculopathy complicated by choroidal neovascularization.

Authors:  M S Blumenkranz; S R Russell; M G Robey; R Kott-Blumenkranz; N Penneys
Journal:  Ophthalmology       Date:  1986-05       Impact factor: 12.079

2.  Smoking and age-related macular degeneration. The POLA Study. Pathologies Oculaires Liées à l'Age.

Authors:  C Delcourt; J L Diaz; A Ponton-Sanchez; L Papoz
Journal:  Arch Ophthalmol       Date:  1998-08

3.  Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey.

Authors:  D S Friedman; J Katz; N M Bressler; B Rahmani; J M Tielsch
Journal:  Ophthalmology       Date:  1999-06       Impact factor: 12.079

4.  Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III.

Authors:  R Klein; B E Klein; S C Jensen; J A Mares-Perlman; K J Cruickshanks; M Palta
Journal:  Ophthalmology       Date:  1999-06       Impact factor: 12.079

5.  The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study.

Authors:  R Klein; B E Klein; S C Jensen; S M Meuer
Journal:  Ophthalmology       Date:  1997-01       Impact factor: 12.079

6.  Smoking and age-related maculopathy. The Blue Mountains Eye Study.

Authors:  W Smith; P Mitchell; S R Leeder
Journal:  Arch Ophthalmol       Date:  1996-12

7.  Senile macular degeneration: a case-control study.

Authors:  L G Hyman; A M Lilienfeld; F L Ferris; S L Fine
Journal:  Am J Epidemiol       Date:  1983-08       Impact factor: 4.897

8.  Systemic hypertension and age-related maculopathy in the Framingham Study.

Authors:  R D Sperduto; R Hiller
Journal:  Arch Ophthalmol       Date:  1986-02

9.  Senile cataract and senile macular degeneration: an investigation into possible risk factors.

Authors:  J M Gibson; D E Shaw; A R Rosenthal
Journal:  Trans Ophthalmol Soc U K       Date:  1986

10.  Refractive error and age-related maculopathy: the Blue Mountains Eye Study.

Authors:  J J Wang; P Mitchell; W Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-10       Impact factor: 4.799

View more
  266 in total

Review 1.  Epidemiology of age-related maculopathy: a review.

Authors:  Redmer van Leeuwen; Caroline C W Klaver; Johannes R Vingerling; Albert Hofman; Paulus T V M de Jong
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

Review 2.  Genetic factors of age-related macular degeneration.

Authors:  Jingsheng Tuo; Christine M Bojanowski; Chi-Chao Chan
Journal:  Prog Retin Eye Res       Date:  2004-03       Impact factor: 21.198

3.  The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study.

Authors:  G McGwin; T A Hall; A Xie; C Owsley
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

Review 4.  Lipid metabolites in the pathogenesis and treatment of neovascular eye disease.

Authors:  Andreas Stahl; Tim U Krohne; Przemyslaw Sapieha; Jing Chen; Ann Hellstrom; Emily Chew; Frank G Holz; Lois E H Smith
Journal:  Br J Ophthalmol       Date:  2011-03-18       Impact factor: 4.638

5.  Synergic effect of polymorphisms in ERCC6 5' flanking region and complement factor H on age-related macular degeneration predisposition.

Authors:  Jingsheng Tuo; Baitang Ning; Christine M Bojanowski; Zhong-Ning Lin; Robert J Ross; George F Reed; Defen Shen; Xiaodong Jiao; Min Zhou; Emily Y Chew; Fred F Kadlubar; Chi-Chao Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

Review 6.  LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis.

Authors:  Yu Tong; Jing Liao; Yuan Zhang; Jing Zhou; Hengyu Zhang; Meng Mao
Journal:  Mol Vis       Date:  2010-10-05       Impact factor: 2.367

7.  Complement factor H polymorphism in age-related macular degeneration.

Authors:  Robert J Klein; Caroline Zeiss; Emily Y Chew; Jen-Yue Tsai; Richard S Sackler; Chad Haynes; Alice K Henning; John Paul SanGiovanni; Shrikant M Mane; Susan T Mayne; Michael B Bracken; Frederick L Ferris; Jurg Ott; Colin Barnstable; Josephine Hoh
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

8.  Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration.

Authors:  Sepideh Zareparsi; Kari E H Branham; Mingyao Li; Sapna Shah; Robert J Klein; Jurg Ott; Josephine Hoh; Gonçalo R Abecasis; Anand Swaroop
Journal:  Am J Hum Genet       Date:  2005-05-13       Impact factor: 11.025

9.  Macular degeneration associated with a novel Treacher Collins tcof1 mutation and evaluation of this mutation in age related macular degeneration.

Authors:  S V Goverdhan; I K Temple; J Self; A J Lotery; M J Dixon; A R Evans
Journal:  Br J Ophthalmol       Date:  2005-08       Impact factor: 4.638

10.  Risk factors for age related maculopathy in a Japanese population: the Hisayama study.

Authors:  M Miyazaki; H Nakamura; M Kubo; Y Kiyohara; Y Oshima; T Ishibashi; Y Nose
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.